1.
Woess K, Macho-Maschler S, van Ingen Schenau DS, Butler M, Lassnig C, Valcanover D, Poelzl A, Meissl K, Maurer B, Brandstoetter T, Vogl C, Koren A, Kubicek S, Orlova A, Moriggl R, Strobl B, Sexl V, van Leeuwen FN, Kuiper RP, Mueller M. Oncogenic TYK2<sup>P760L</sup&gt; kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. Haematologica; https://doi.org/10.3324/haematol.2021.279848 [Early view].